Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis

Background: Clinical trials have shown that the use of trastuzumab deruxtecan (DS-8201) alone is expected to provide novel therapeutic options for HER2-low/positive patients. Nevertheless, there are some variations in the efficacy of trial results, with potential risks at the safety level. Most DS-8...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zongyu, Guo, Shangwen, Xue, Haoyi, Li, Luying, Guo, Yuyuan, Duan, Sinuo, Zhu, He
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324614/
https://www.ncbi.nlm.nih.gov/pubmed/37426807
http://dx.doi.org/10.3389/fphar.2023.1183514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324614/
https://www.ncbi.nlm.nih.gov/pubmed/37426807
http://dx.doi.org/10.3389/fphar.2023.1183514

Ejemplares similares